title: Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study.
authors.affiliation: CERMEP Cyclotron Unit, Hôpital Neurologique Pierre Wertheimer, Lyon, France.
authors.forename: C
authors.initials: C
authors.lastname: Dentresangle
authors.forename: L
authors.initials: L
authors.lastname: Veyre
authors.forename: D
authors.initials: D
authors.lastname: Le Bars
authors.forename: C
authors.initials: C
authors.lastname: Pierre
authors.forename: F
authors.initials: F
authors.lastname: Lavenne
authors.forename: P
authors.initials: P
authors.lastname: Pollak
authors.forename: J
authors.initials: J
authors.lastname: Guerin
authors.forename: J C
authors.initials: JC
authors.lastname: Froment
authors.forename: E
authors.initials: E
authors.lastname: Brousolle
mesh_terms: D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D001931:Brain Mapping; D002230:Carbidopa / Q000008:administration & dosage / Q000009:adverse effects; D002250:Carbon Radioisotopes; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000503:physiopathology; D004295:Dihydroxyphenylalanine; D004338:Drug Combinations; D005260:Female; D005462:Fluorine Radioisotopes; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000503:physiopathology; D020891:Raclopride; D017448:Receptors, Dopamine D2 / Q000187:drug effects / Q000502:physiology*; D014055:Tomography, Emission-Computed
chemical_list: D000978:Antiparkinson Agents; D002250:Carbon Radioisotopes; D004338:Drug Combinations; D005462:Fluorine Radioisotopes; D017448:Receptors, Dopamine D2; C009265:carbidopa, levodopa drug combination; D020891:Raclopride; D007980:Levodopa; D004295:Dihydroxyphenylalanine; D002230:Carbidopa